LIMN
Liminatus Pharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
LIMN Profile
Liminatus Pharma, Inc.
A preclinical biopharmaceutical company developing novel immunomodulatory cancer therapies
6 Centerpointe Drive #625, La Palma, CA 90623
--
Liminatus Pharma, Inc., a Delaware corporation, was founded on November 23, 2022. Liminatus is a preclinical stage biopharmaceutical company developing novel immunomodulatory cancer therapies. The company's candidate IBA 101 is a humanized anti-CD47 monoclonal antibody. Initial indications for next-generation CD47 checkpoint inhibitors are expected for patients with advanced solid cancers, including non-small cell lung cancer. As a leading global biopharmaceutical company, the company's vision is to develop a broad range of transformative therapies for cancer patients.